Allarity Therapeutics, Inc. (ALLR)
NCM · Healthcare · Biotechnology
Closing price as of 2026-08-12 · Source: TEK2day Finance
Key Metrics
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 320K | 25K |
| Operating Income | (4.1M) | (2.5M) | (2.9M) | (2.7M) |
| Net Income | (2.3M) | (2.8M) | (3.4M) | (2.8M) |
| Diluted EPS | $-0.15 | $-0.19 | N/A | $-0.17 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 320K |
| Operating Income | (16.9M) | (17.1M) | (17.5M) | (12.6M) |
| Net Income | (16.1M) | (11.9M) | (24.5M) | (11.2M) |
| Diluted EPS | $-31,799.09 | $-6,031.31 | $-15.65 | $-0.78 |